Related Experiment Videos
Aspirin desensitization in patients with AERD
1Division of Allergy, Asthma, and Immunology, Scripps Clinic and the Scripps Research Institute, La Jolla, CA 92037, USA.
Clinical Reviews in Allergy & Immunology
|April 2, 2003
Summary
Aspirin desensitization offers a daily treatment option for Aspirin Exacerbated Respiratory Disease (AERD). This therapy improves clinical outcomes for many AERD patients, reducing the need for other medications.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Aspirin Exacerbated Respiratory Disease (AERD) is a chronic condition.
- Current treatments may not be sufficient for all AERD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of aspirin desensitization in AERD patients.
- To assess the long-term benefits of daily aspirin therapy in AERD.
Main Methods:
- Aspirin desensitization protocol for AERD patients.
- Daily aspirin administration (650 mg BID) for at least one year.
- Monitoring of clinical improvement and adverse effects.
Main Results:
- 67% of patients (115/172) showed clinical improvement with daily aspirin.
- Reduced need for systemic and topical corticosteroids observed in responders.
- 16 patients did not improve, and some experienced side effects or discontinued treatment.
Conclusions:
- Aspirin desensitization is a viable therapeutic option for AERD.
- Daily aspirin therapy can significantly improve AERD management, especially for those unresponsive to other treatments.
- Patients with severe nasal polyps or those requiring systemic steroids are good candidates for this intervention.